Hatteras Financial (NYSE:
HTS) shares reached a new 52-week low of $16.173. Hatteras Financial's trailing-twelve-month profit margin is -6.57%.
Myriad Genetics (NASDAQ:
MYGN) shares touched a new 52-week low of $20.14. Myriad Genetics expressed concerns over CMS not valuing BRCA 2 gene in 81211 code, CMS 81211 payment rate. Mizuho Securities downgraded the stock from Buy to Neutral.
Gyrodyne Co. of America (NASDAQ:
GYRO) shares touched a new 52-week low of $67.52. Gyrodyne Co. of America shares have dropped 4.52% over the past 52 weeks, while the S&P 500 index has gained 29.11% in the same period.
Can-Fite BioPharma (NYSE:
CANF) shares reached a new 52-week low of $5.551 after the company's subsidiary OphthaliX (OTC:
OPLI) reported that its phase III study with its licensed drug CF101 for moderate-to-severe dry eye syndrome did not meet primary efficacy endpoint.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
